The biopharmaceutical industry prevailed in California as the ballot initiative Proposition 61 to limit drug prices was defeated Nov. 8 by nearly an eight-point margin. But the defeat does not forestall future ballot efforts aimed at pharmaceutical price controls.
The vote on Prop 61 ended up with 53.8% voting no and 46.2% voting yes. If approved, it would have regulated prescription drug prices by requiring state agencies to pay no more than what the US Department of Veterans Affairs pays for a drug, which would effectively extend the discounts biopharma companies make available to the VA health system to people covered under other state health care programs, such as Medi-Cal and the California Public Employees Retirement System
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?